Results 31 to 40 of about 27,421 (247)

OSTEOPROTEGERIN, RANK, RANKL [PDF]

Biomedical Papers, 2001
Osteoprotegerin, RANK (Receptor Activator of Nuclear factor kappa B) and RANKL (Receptor Activator of Nuclear faktor kappa B ligand) became the aim of intensive research. RANK is considered as a hematopoietic surface receptor controlling osteoclastogenesis and calcium metabolism.
D, Stejskal, J, Bartek, R, Pastorková, V, Růzicka, I, Oral, D, Horalík   +5 more
openaire   +2 more sources

The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption [PDF]

Journal of Bone and Mineral Research, 2000
Abstract Although multiple hormones and cytokines regulate various aspects of osteoclast formation, the final two effectors are osteoprotegerin ligand (OPG-L)/osteoclast differentiation factor (ODF), a recently cloned member of the tumor necrosis factor superfamily, and macrophage colony–stimulating factor.
L C, Hofbauer, S, Khosla, C R, Dunstan, D L, Lacey, W J, Boyle, B L, Riggs   +5 more
openaire   +2 more sources

Serum OPG and RANKL Levels as Risk Factors for the Development of Cardiovascular Calcifications in End-Stage Renal Disease Patients in Hemodialysis

Life, 2023
Cardiovascular calcifications (CVC) are frequently observed in chronic kidney disease (CKD) patients and contribute to their cardiovascular mortality. The aim of the present study was to investigate the impact of osteoprotegerin (OPG)/Receptor Activator ...
Michalis Spartalis, Efstratios Kasimatis, Eleni Liakou, Erasmia Sampani, Georgios Lioulios, Michalis Christodoulou, Stamatia Stai, Eleni Moysidou, George Efstratiadis, Aikaterini Papagianni   +9 more
doaj   +1 more source

Could osteoprotegerin serve as a marker of metabolic syndrome?

Current Issues in Pharmacy and Medical Sciences, 2013
There has been a dramatic increase in the worldwide prevalence of obesity, which is associated with the development of several chronic diseases such as metabolic syndrome, type 2 diabetes and cardiovascular diseases.
Anna Maria Dąbrowska, Jerzy S. Tarach, Beata Wojtysiak-Duma, Arleta Malecha-Jędraszek, Anna Toruń-Jurkowska, Janusz Kudlicki, Helena Donica   +6 more
doaj   +1 more source

Serum Osteoprotegerin Level Is Negatively Associated with Bone Mineral Density in Patients Undergoing Maintenance Hemodialysis

Medicina, 2021
Background and Objectives: Osteoprotegerin (OPG), a potent osteoclast activation inhibitor, decreases bone resorption and plays a role in mediating bone mineral density (BMD).
Chia-Wen Lu, Chih-Hsien Wang, Bang-Gee Hsu, Jen-Pi Tsai   +3 more
doaj   +1 more source

Risk Factors Associated With Altered Circulating MicroRNA‐125b and Their Influences on Uremic Vascular Calcification Among Patients With End‐Stage Renal Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background MicroRNA‐125b (miR‐125b) has been shown to regulate vascular calcification (VC), and serum miR‐125b levels are a potential biomarker for estimating the risk of uremic VC status.
Chia‐Ter Chao, Tzu‐Hang Yuan, Hsiang‐Yuan Yeh, Hsuan‐Yu Chen, Jenq‐Wen Huang, Huei‐Wen Chen   +5 more
doaj   +1 more source

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Elevated levels of osteoprotegerin, a secreted tumor necrosis factor–related molecule, might be associated with adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital admission,
Thor Ueland, Axel Åkerblom, Tatevik Ghukasyan, Annika E. Michelsen, Pål Aukrust, Richard C. Becker, Maria Bertilsson, Anders Himmelmann, Stefan K. James, Agneta Siegbahn, Robert F. Storey, Frederic Kontny, Lars Wallentin   +12 more
doaj   +1 more source

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss

, 2010
Anne-Priscille Trouvin, Vincent GoëbDepartment of Rheumatology, Rouen University Hospital, Rouen, FranceAbstract: Bone remodeling requires a precise balance between resorption and formation.
Vincent Goëb, Vincent Goëb, Anne-Priscille Trouvin, null Trouvin Anne-Priscille   +3 more
core   +1 more source

Polymorphisms within RANKL and Osteoprotegerin Genes in Low Bone Mass among Postmenopausal Indonesian Women [PDF]

, 2019
Objective:Prior studies have shown that receptor activator of nuclear factor-B ligand (RANKL) and osteoprotegerin (OPG) have an essential role in bone remodeling and osteoporosis.
Herawati Sudoyo, Andri Lubis, Ambrosius Purba, Sri Widia Jusman, Murdani Abdullah, Ignatio Rika Haryono, Ermita Ibrahim Ilyas, Angela Tulaar   +7 more
core   +1 more source

Therapeutic implications of osteoprotegerin

Cancer Cell International, 2009
Osteoprotegerin (OPG), a member of the tumor necrosis factor (TNF) receptor superfamily, contributes determinatively to the bone remodeling as well as to the pathogenetic mechanism of bone malignancies and disorders of mineral metabolism. There is additional evidence that OPG can promote cell survival by inhibiting TNF-related apoptosis-inducing ligand
Fili, S., Karalaki, M., Schaller, B.
openaire   +4 more sources